



Mission:

We provide patients with universal access to valuable products created with the participation of pharmacists.



GRUPA NEUCA



Synoptis Pharma is part of the NEUCA group, the largest Polish distributor of pharmaceuticals, which has been supporting independent pharmacies for 30 years.

Synoptis Pharma is a polish pharmaceutical manufacturer and distributor (TOP 10 of OTC drugs).

Our offer includes high-quality prescription drugs, dietary supplements, medical devices, hygiene products, personal protective equipment and dermocosmetics in response to patients' needs and the expectations of doctors and pharmacists.



GRUPA NEUCA




By taking advantage of the NEUCA Group's experience and scale, we achieve synergy effects.

We combine the knowledge and experience of our medical facilities, doctors and scientists.

We gain knowledge from, among others: from cooperation with scientists conducting clinical trials.








Synoptis Pharma achieved a double sales growth rate in Q1 2024 higher than the non-RX market, thus moving to eighth place in the ranking TOP 20 concerns in Poland


TOP 20 companies on the non-RX market (according to sales value) along with the evolution of YTD 03/2024 vs YTD 03/2023*





In a declining packaging market, Synoptis Pharma remains one of the few companies that recorded an increase in sales volume in Q1 2024

TOP 20 companies on the non-RX market (by sales volume) along with the evolution of YTD 03/2024 vs YTD 03/2023*



Non-RX PPG (YTD): -0.6%

Sales (million pieces)Sales dynamics (%)



Synoptis Pharma does not slow down, leading the way subsequent registration processes

REGISTRATION OF SYNOPTIS PHARMA MEDICINAL PRODUCTS IN Q1 2024:

→ We are currently responsible for 17 ongoing registration procedures, including as many as thirteen products in OTC status and four in Rx status.

→ In Q1 2024, we submitted one application to start registration of the product in OTC status, which after registered, will join the group of products used in the treatment of allergy symptoms.

→ We have received a set of approved changes to the OTC availability categories for the following products: Cetoalergedd, Levalergedd, Silderos, Tadalafil APTEO MED.

Check our portfolio: <u>https://synoptispharma.pl/portfolio</u>







For more information contact our team:



Rafał Bednarczyk Strategic Marketing Director <u>rafal.bednarczyk@synoptispharma.pl</u> +48 505 483 608

Paweł Moćko

Drug Development Manager pawel.mocko@synoptispharma.pl +48 789 803 643

Aleksandra Jasiak-Krzemińska

Patent Attorney <u>aleksandra.jasiak-krzeminska@synoptispharma.pl</u> +48 572 080 824

Paulina Surmacewicz

Strategic Marketing Coordinator paulina.surmacewicz@synoptispharma.pl +48 515 735 773



https://www.linkedin.com/company/synoptis-pharma

